Therapy with the fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists (IDegLira) is an effective treatment in patients with uncontrolled type 2 diabetes mellitus (T2DM).

The aim of this real-world study was to evaluate IDegLira in an Italian population of T2DM patients.

Improvement of glycemic control, no gain in body weight and body mass index and reductions in fasting plasma glucose and number of concomitant diabetic medications were observed following the switch to IDegLira therapy.

The findings show that in a real-world setting, the switch to IDegLira treatment is a valid therapeutic option for patients with T2DM who are unable to achieve glycemic control targets and/or report side effects with other insulin therapies.